Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

ACC pipeline

Trial arms side by side.

One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.

ClassNone selected

No arms selected. Choose a drug, an arm, or a preset.

20 of 25 arms with a reported figure. Choose arms to narrow the chart.

ArmReported safety
Emiltatug Ledadotin (Emi-Le, XMT-1660) Phase 1 doses (not stated in source)n/r
Emiltatug Ledadotin (Emi-Le, XMT-1660) Phase 1 doses (not stated in source)n/r
Emiltatug Ledadotin (Emi-Le, XMT-1660) Phase 1 doses (not stated in source)grade 3 treatment-related adverse events: 79.2%, ASCO 2026treatment-related discontinuation: 2.1%, ASCO 2026dose reduction: 45.8%, ASCO 2026
RGT-61159 at or below RP2D (mixed doses)n/r
REM-422 24 mgn/r
REM-422 12 to 48 mgn/r
REM-422 24 mgtreatment-related epistaxis (all grade 1 or 2): 60%, cutoff 01.07.2026treatment-related fatigue (all grade 1 or 2): 60%, cutoff 01.07.2026
Osugacestat (AL101, BMS-906024) 4 mgpatients with serious adverse events: 23 patients (of 45), final
Osugacestat (AL101, BMS-906024) 6 mgpatients with serious adverse events: 26 patients (of 42), final
Lenvatinib (off Label) 24 mggrade 3 or 4 hypertension: 28.1%, primary analysisdiscontinued for drug-related issues: 18 patients (of 32), primary analysis
Lenvatinib (off Label) 24 mggrade 3 or higher treatment-related adverse events: 50%, primary analysis
Lenvatinib (off Label) not stated in sourcegrade 3 or higher toxicity: 71%, ASCO 2023 (search record)
Axitinib (off Label) 5 mgn/r
Axitinib (off Label) nonen/r
Axitinib (off Label) axitinib 5 mg twice daily + avelumabserious treatment-related adverse events: 29%, primary analysis
Axitinib (off Label) as aboven/r
Axitinib (off Label) as aboven/r
Rivoceranib 700 mggrade 3 or higher treatment-related adverse events: 70%, primary analysisdiscontinued for toxicity: 20%, primary analysis
Amivantamab not stated in sourcepatients with serious adverse events: 7 patients (of 21), results posted
Regorafenib (off Label) not stated in sourcepatients with serious adverse events: 14 patients (of 38), results posted

A count stays a count. This page does not turn a count into a percent.

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.